Brainy efforts underway, but still some way to go for neuro drug developers
Main U.S. indexes sharply higher; Nasdaq, Dow up 1.3%
Cons Disc leads S&P sector gainers; Utilities sole loser
Euro STOXX 600 index up 1.3%
Dollar rises; gold edges up; crude, up >1%, bitcoin up 0.4%
U.S. 10-Year Treasury yield edges up to ~4.33%
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com
BRAINY EFFORTS UNDERWAY, BUT STILL SOME WAY TO GO FOR NEURO DRUG DEVELOPERS
An unmet need in neurological conditions has stirred up anticipation for trial data for drugs being developed for neurological conditions like depression, Alzheimer's disease, and dementia that affect millions of patients worldwide, Canaccord Genuity analysts said on Friday.
The brokerage said some recent wins with Eisai 4523.T and Biogen's BIIB.O Leqembi and Eli Lilly's LLY.N Kisunla for Alzheimer's, along with Bristol Myers Squibb's BMY.N Cobenfy for schizophrenia, represent significant advances in their fields.
It estimates that about 57 products are in development for major depressive disorder, including 14 for treatment-resistant depression, 11 for bipolar depression, and 5 for postpartum depression that affects new mothers.
Canaccord said it is looking forward to late-stage trial data from Johnson & Johnson's JNJ.N aticaprant and Neumora Therapeutics' NMRA.O navacaprant, both in development for major depressive disorder.
"Overall, we believe biopharma's depression-focused pipeline remains healthy" said Canaccord, but added that there was still a long way to go due to some diseases being poorly understood.
Canaccord added that successes in Alzheimer's with Leqembi and Kisunla have come despite the challenges in understanding such neurodegenerative conditions.
Among newer drugs in development, the brokerage highlighted Roche's ROG.S trontinemab, designed to ferry the drug across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain - in hopes of getting more of the treatment into the brain.
Canaccord said Cervomed's CRVO.O neflamapimod could be a "major advance for patients."
Cervomed is developing the drug to treat dementia with Lewy bodies, the second most common type of dementia after Alzheimer's and an indication that sees fewer investments, said Canaccord.
(Christy Santhosh)
*****
FOR FRIDAY'S EARLIER LIVE MARKETS POSTS:
JOBS REPORT DRILL-DOWN: IS DIRE DATA A BLIP OR TREND? - CLICK HERE
U.S. STOCKS RISE AFTER PAYROLLS AS AMAZON LEADS - CLICK HERE
U.S. STOCK FUTURES ADD SLIGHTLY TO GAINS, YIELDS FALL, AFTER JOBS DISAPPOINT - CLICK HERE
COULD OCTOBER PAYROLLS BE NEGATIVE? - CLICK HERE
EUROPEAN EARNINGS: BETTER BUT STILL MIXED - MORGAN STANLEY - CLICK HERE
UK GILTS: TRUSSED UP? - CLICK HERE
EUROPEAN SHARES BOUNCE, STILL SET FOR WEEKLY FALL - CLICK HERE
EUROPE BEFORE THE BELL: FUTURES STEADY BEFORE JOBS DATA - CLICK HERE
A NOVEMBER TO REMEMBER... -CLICK HERE
Early trade Nov 1 https://tmsnrt.rs/4f6WHRV
Nonfarm payrolls https://reut.rs/3AaNOYA
Inflation gauges https://reut.rs/40sVSP5
Labor market participation https://reut.rs/4easqAj
Unemployment by duration https://reut.rs/3YKrmPl
Unemployment by race and ethnicity https://reut.rs/48u6jDK
Aset Terkait
Berita Terbaru
Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.
Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.
Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.
